Sijmen de Vries has been nominated as the new chief executive officer of Pharming Group NV to succeed Francis J Pinto who is retiring. Dr de Vries’ nomination is expected to be approved at an extraordinary general meeting of shareholders to be held on 13 October 2008.
Currently CEO of the Swiss company, 4-Antibody AG, Dr de Vries has held numerous executive positions in the pharmaceutical and biotechnology industries, including at Novartis and SmithKline Beecham Pharmaceuticals. He also holds non-executive directorships in two private life science companies.
Dr Pinto is retiring as Pharming’s chief executive, but will remain with the company as a non-executive chairman of the management board until the next annual general meeting of shareholders in 2009.
Based in Leiden, the Netherlands, Pharming is developing products for the treatment of genetic disorders and ageing diseases as well as specialty products for surgical indications.
Copyright 2008 Evernow Publishing Ltd